Science-first.
Execution-driven.
Scientific Diligence
We evaluate molecular mechanisms, clinical data packages, and competitive landscapes with the rigour of a scientific advisory board — not a financial model.
Capital Markets Analysis
We assess why a company is undervalued: IR failures, narrative gaps, institutional neglect. We identify the specific levers that will unlock market recognition.
Structured Investment
We deploy US$5–30 million via PIPE, ensuring our capital directly funds clinical advancement rather than secondary market liquidity.
Operational Support
Post-investment, we provide hands-on assistance in CMC (Chemistry, Manufacturing & Controls) and clinical operations — bridging the gap between discovery and IND filing.
CMC & Clinical Operations Support
Beyond Capital
We are operators, not just allocators. Our value extends well beyond the term sheet.
PIPE Investment
US$5–30 million deployed through newly issued public shares, providing direct growth capital to clinical-stage programs.
CMC Advisory
Chemistry, Manufacturing & Controls expertise to accelerate IND-enabling studies and regulatory submissions.
Clinical Operations
Trial design, CRO selection, site activation, and protocol optimization — from Phase I through proof-of-concept.
Capital Markets Strategy
Investor relations restructuring, narrative development, and institutional outreach to close the valuation gap.
Scientific Network
Access to our network of KOLs, academic collaborators, and regulatory advisors across oncology, rare disease, and CNS.
Bench-to-Clinic Bridge
We help founders and scientists navigate the translational gap — from promising molecule to clinical-stage asset.